Intellia Therapeutics Stock Analysis

Intellia Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.52. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Intellia Therapeutics recorded a loss per share of 5.23. The entity had not issued any dividends in recent years. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Intellia Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 485 people. To find out more about Intellia Therapeutics contact John MD at 857 285 6200 or learn more at https://www.intelliatx.com.

Intellia Therapeutics Investment Alerts

Intellia Therapeutics Upcoming and Recent Events

Intellia Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.25 B.

Technical Drivers

As of the 20th of July, Intellia Therapeutics retains the Risk Adjusted Performance of 0.1428, downside deviation of 6.42, and Market Risk Adjusted Performance of 0.4576. Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of Intellia Therapeutics, as well as the relationship between them.

Intellia Therapeutics Price Movement Analysis

Intellia Therapeutics Insider Trading Activities

Intellia Therapeutics Outstanding Bonds

Intellia Therapeutics Predictive Daily Indicators

Intellia Therapeutics Forecast Models

Intellia Therapeutics' time-series forecasting models are one of many Intellia Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Intellia Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Intellia Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Intellia shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Intellia Therapeutics. By using and applying Intellia Stock analysis, traders can create a robust methodology for identifying Intellia entry and exit points for their positions.

When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.